TILT Biotherapeutics Ltd’s Post

[#Meet2Win] 📅 May 16-17, 2024 📍 Bordeaux, France   Virginie Carrincazeaux was part of Meet2Win 2024, the European partnering convention entirely dedicated to open innovation in #oncology. Meet2win brought together leading #experts in this field. Creapharm, a Myonex company supports Pharma and Biotech companies developing #cancer therapies with: ➡ #CTSM: decades of exeriences in Clinical Trial Supply management in oncology phase I-III studies ➡ #biobanking: highly-secured storage of the most valuable research biospecimen ➡ #ATMP supply chain: with a strong expertise in ultra-cold chain management, Creapharm handles storage, packaging and logistics of the most innovative therapies, such as CAR-T cells. Thank MATWIN for arranging an event with such a high scientific level.

Learn about life science in Maryland. The most popular indication for biotechs is #oncology, with the majority of assets being in preclinical development. Read our analysis on the life sciences industry in Maryland, made in cooperation with the Maryland Department of Commerce https://lnkd.in/e-AMpqSd

Antibody-drug conjugates (ADCs) deliver highly-potent drug payloads to precisely kill cancer cells. In our Piper Sandler BioInsights deep-dive report “Antibody-Drug Conjugates – Top1 of Mind,” senior biotech research analysts Joseph Catanzaro, Chris Raymond, Allison Bratzel, CFA and Ted Tenthoff share their analysis of the progress, innovation and opportunity in this rapidly-emerging field.         #PSCbioinsights #biotech #oncology #biopharma #ADCs #bioinsights

Get more involved in your study results today! With CrownLink™ you can save time accessing your preclinical oncology in vivo study results and achieve data efficiency. Designed to fit your needs, CrownLink offers: ✅Free access ✅Online visualization ✅Monitor study data updates Register today to get started! https://bit.ly/3ZC0cZS #Preclinical #Oncology #Data #Biotech #Bioscience

2023 Private Rounds by Therapeutic Area Private capital flow concentrated in early technology and Oncology/Immunology. This could have significant implications for available in-licensing volume in the medium term - Discovery platforms (mostly in Boston) have been the most attractive for capital raises this year - Oncology and Autoimmune target indications are mechanistic similar and account for almost 50% of all private capital placements in 2023 #biotechnology #funding #drugdevelopment

ExoProTher eagerly awaits the State-of-the-Art Envision NTA Machine from HYPERION ANALYTICAL We are excited to share that the brand-new, and Israel's first, Nanoparticle Tracking Analysis (NTA) machine of this kind – Envision from Hyperion Analytical LLC, is on the way to ExoProTher’s labs. The Envision will significantly enhance our analytical capabilities and data reliability. Our investment in the HYPERION NTA Envision underscores our commitment to pioneering science and best quality data behind the development of p53 replacement therapy for oncology indications.   Watch this space for more updates!   #nanoparticletrackinganalysis #innovation #p53replacementtherapy #biotechnology #oncology

This is the kind of progress we, 28 Ventures, expect to see from our portfolio companies, like CytoMed Therapeutics (NASDAQ: GDTC)… GDTC patents granted, on the forefront of cancer research and therapy: https://bit.ly/48wousm "Such progress further expands the Company's current patent portfolio to three countries, consisting of and including patents granted in the US and China for our licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology which is expected to start phase I clinical trial in Singapore soon." #drugdevelolpment #drugresearch #cancerresearch #cancertherapy #CART #immunotherapy #investing #privateequity #privatecapital #gopublic #venturecapital #publicventure #publicventurecapital #limitedpartnership #limitedpartnerships #boutiqueventure #VC #boutiquevc #preIPO #startupcapital #LPs #valueinvesting CytoMed Therapeutics Limited

“Looking beyond the lampposts, looking beyond the known biology, is what Recursion’s platform promises to unlock.” ◾ The Bayer-Recursion collaboration brings together Recursion’s technology-forward and AI-leading emphasis and Bayer’s legacy of drug development. The $1.5B deal announced last October in precision oncology already has one joint project now rapidly advancing to Lead Series nomination. ◾ We are on track to complete 25 unique multimodal data packages in Q3. ◾ The Recursion operating system allows Bayer to scale up data generation, explore a large number of oncology targets simultaneously, and “do unbiased discovery.” ◾ Announced at Download Day, Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory and intuitive research environment for scientists on both sides. #techbio #ai #platform #partnership #pharma #cancer #oncology #downloadday

Yesterday, Gordon Haner, MBA, LATG, ILAM was onsite at EMD Serono, Inc. for a Biotech Vendor Services, Inc. vendor show! Thank you to all those who came to talk to Gordon about GemPharmatech's mouse models and preclinical services. If you are in the #bostonbiotech community make sure to reach our to Gordon if you do preclinical research with mouse models. Also a thank you to Matthew Potter and BVS! See you again soon, new EMD and MilliporeSigma friends! #preclinicalresearch #oncology #autoimmune #vendorshow #bvs #bvsvendorshow

ATTN #BIO2024: Today at 2:30 pm, our CEO, Bob Linke, gives a company presentation about OSM-0205, our lead product. We look forward to providing an update on our plans for OSM-0205, which is poised to initiate clinical development later this year. OSM-0205 is a preventative treatment to help patients avoid the painful and debilitating effects of chemotherapy-induced peripheral neuropathy (CIPN), common amongst taxane-based chemotherapies, including the leading breast cancer chemotherapy treatment. CIPN affects as many as 80% of these cancer patients and can significantly impact both quality of life and survival. Stop by to see our company presentation or request a meeting with our CEO, Bob Linke through, the Biotechnology Innovation Organization (BIO) One-on-One Partnering™ System: https://lnkd.in/eEDtKaAK #oncology #biotech #investors